U.S. Overhaul of Health Aid Raises Concerns for HIV and Malaria Treatment

The United States is undergoing a significant transformation in its approach to delivering medical supplies for HIV and malaria to lower-income countries. This change, which has raised alarms among health officials and aid organizations, involves the cessation of the Global Health Supply Chain Program managed by the private contractor Chemonics. Since its inception in 2016, this program has facilitated the delivery of over $5 billion in health products to 90 countries, primarily in sub-Saharan Africa and Asia. The U.S. State Department has instructed its missions in 17 African nations and Haiti to halt the program by May 30, with the contract with Chemonics officially ending on September 30, 2024.

US health aid overhaul raises new fears for HIV, malaria lifelines

The transition away from contractor-led programs is part of the U.S. administration's America First Global Health Strategy, which aims to eliminate inefficiencies and reduce costs associated with foreign aid. The U.S. government is now pursuing bilateral agreements with recipient countries, having signed 28 such health pacts, and plans to rely on private logistics firms for distribution. However, the rapid pace of this overhaul has led to warnings from multiple sources about potential shortages of essential medical supplies, including malaria treatments for children and HIV prevention tools. Aid experts have expressed concerns that the timeline for the transition is overly ambitious, particularly in regions with fragile supply chains.

US health aid overhaul raises new fears for HIV, malaria lifelines

In light of these changes, the U.S. is reportedly in discussions with the Global Fund to Fight AIDS, Tuberculosis and Malaria, which currently manages approximately $2 billion annually in health product procurement. The Global Fund's existing infrastructure could potentially serve as a new channel for U.S.-funded supplies. However, sources indicate that the proposed timeline for this transition, initially suggested for late 2027, may be unrealistic given the complexities of ordering and distributing medical products in hard-to-reach areas.

The Straits Times

Critics of the U.S. strategy argue that the abrupt shift could disrupt treatment for millions. For instance, in Zimbabwe, the withdrawal of U.S. funding has raised concerns about the future availability of lenacapavir, a long-acting injectable HIV prevention drug. Health workers have reported gaps in HIV prevention programs and shortages of malaria treatments, highlighting the immediate impact of the funding retreat. The U.S. Embassy in Zimbabwe has denied allegations of seeking access to sensitive data as part of funding negotiations, which have stalled amid concerns from the Zimbabwean government.

Zimbabwe’s new HIV drug at risk as US funding retreats

• “But the speed of the changes to how the US delivers aid has already caused problems around the world, including shortages of malaria drugs for children and gaps in HIV prevention.” — U.S. State Department spokesperson

The Straits Times

• “If it so happens that the programme is discontinued, it puts me back at risk.” — Nyasha Sayi, HIV prevention program participant

Zimbabwe’s new HIV drug at risk as US funding retreats

• “Net: “Lenacapavir will remain in the body for another six months.” — Emily Gwavava, consultant in Zimbabwe’s lenacapavir program

Zimbabwe’s new HIV drug at risk as US funding retreats

As the U.S. continues to reshape its health aid strategy, the effectiveness of the new bilateral agreements and the collaboration with the Global Fund will be closely monitored. The potential for service disruptions remains a critical concern, with millions relying on consistent access to life-saving medical supplies.

The Straits Times